De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

92 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2022-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

NCT05051605

Liver Transplant

UNKNOWN

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

NCT00550849

Liver Disease

TERMINATED PHASE1/PHASE2

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

NCT05209100

Non-Alcoholic Fatty Liver Disease

ACTIVE_NOT_RECRUITING

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease

NCT05167305

Liver Diseases

COMPLETED

Integrated Approaches for Identifying Molecular Targets in Liver Disease

NCT03915002

Alcoholic Liver Disease Non-Alcoholic Fatty Liver Disease Steatohepatitis, Nonalcoholic +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Single Transplant 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tolerant

patients who withdraw IS drugs after LT

Immunosuppressive

Intervention Type DRUG

compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

non tolerant

patients who couldn't wean IS drugs

Immunosuppressive

Intervention Type DRUG

compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunosuppressive

compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* single LT recipients with an attempt of IS withdrawal
* minimum 5 years follow-up

Exclusion Criteria

* Liver transplant combined with other organs
* Presence of metabolic syndrome and/or NASH and/or NAFLD as an indication for liver transplantation
* Loss of patient to follow-up

Minimum Eligible Age

49 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No